Last reviewed · How we verify
Risperidone microspheres
At a glance
| Generic name | Risperidone microspheres |
|---|---|
| Also known as | Risperdal Consta |
| Sponsor | Northwell Health |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy (PHASE4)
- Risperdal Consta for Bipolar Disorder (PHASE3)
- Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence (PHASE4)
- An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia (PHASE4)
- Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA)
- A Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres (e-STAR)
- An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment (PHASE4)
- An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Risperidone microspheres CI brief — competitive landscape report
- Risperidone microspheres updates RSS · CI watch RSS
- Northwell Health portfolio CI